 |
|
 |
|
|
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada. |
||
|
2008 ICAAC / IDSA Joint Meeting MX-2401 Poster Presentations Saturday, October 25th, 2008 12:15 PM EDT Washington, D.C. Click Here for ICAAC / IDSA 2008 Website
2008 Annual Report (PDF)
SEDAR FILINGS (click here)
|
|
Monday, May 11, 2009 (PDF) – MIGENIX Provides Update on OmigardTM Program
Friday, April 3, 2009 (PDF) – MIGENIX Provides Update on Celgosivir Program
Tuesday, March 17, 2009 (PDF) - MIGENIX Reports Third Quarter Fiscal 2009 Financial Results
Monday, March 16, 2009 (PDF) - MIGENIX Completes Rights Offering
Thursday, March 12, 2009 (PDF) - MIGENIX Announces OmigardTM Phase III Clinical Trial Results
Friday March 6, 2009 (PDF) - MIGENIX Provides Update on Rights Offering
|
